Promising Results Found In Clinical Trial For Treatment Against Rare Form of Blood Cancer

Researchers From Japan Find New Treatement Protocol Against Blood Cancer

A study led by researchers from Nagoya University and Mie University in Japan claims that a combination of chemotherapy with a drug known as "rituximab", along with treatment aimed at secondary Central Nervous System (CNS) problem, has proven effective in patients afflicted with a rare subtype of Lymphoma, which is simply known as blood cancer.

"We considered that rituximab-containing chemotherapies combined with treatment for the secondary CNS problems could lead to further improvement in the clinical outcome," said study researcher Kazuyuki Shimada from Nagoya University.

No Effective Treatment Against The Disease

Lymphoma is a type of blood cancer that develops from lymphocytes (a type of white blood cell). It has many subtypes. According to the study published in the journal 'Lancet Oncology', there is no effective treatment for the rare disease.

The disease tends to affect the elderly, for whom standard high-dose chemotherapy may have serious side-effects, and the patients are at a high risk of developing subsequent CNS disorders even with treatment.

cancer cells
Representational Picture Pixabay

A novel treatment protocol with fewer side-effects and which also tackles secondary CNS involvement is needed, and this is exactly what a group of scientists, led by researchers from Nagoya University and Mie University in Japan, attempted to test in a new clinical trial.

A previous "retrospective" study involving the analysis of medical records of patients who had undergone standard chemotherapy combined with the drug "rituximab" showed that this line of treatment is more promising than standard treatment alone, but it does not solve the problem of secondary CNS involvement.

Promising Results From Treatment Protocol

With this consideration, the research team conducted a Phase 2 multicentre clinical trial, where they administered their proposed treatment to 38 enrolled patients (aged 20 to 79 years and without CNS disorders at the time of cancer diagnosis) and monitored their conditions over the long term.

Overall, their treatment protocol appears to be promising: 76 percent of the enrolled patients reached the primary goal of two-year survival without disease progression and 92 percent reached two-year overall survival.

The disease affected the CNS in only 3 percent of patients. The findings also showed that the toxicity of the treatment was found below, and all adverse effects were manageable, with very few serious complications.

This means that although further study is necessary, this protocol can be adopted in clinical practice in the very near future. The findings of this clinical trial are certainly quite promising. With only minor refinements to the proposed treatment protocol, patients with 'Intravascular Large B-cell Lymphoma' could have an edge in their fight against cancer, the researchers noted.

(With inputs from agencies)